Cargando…
The Nitric Oxide Donor [Zn(PipNONO)Cl] Exhibits Antitumor Activity through Inhibition of Epithelial and Endothelial Mesenchymal Transitions
SIMPLE SUMMARY: Nitric oxide (NO) plays a critical pathophysiological role in cancer by modulating several processes, such as angiogenesis, tumor growth, and metastatic potential. The aim of this study was to characterize the antitumor effects of a novel NO donor, [Zn(PipNONO)Cl], on the processes o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454450/ https://www.ncbi.nlm.nih.gov/pubmed/36077778 http://dx.doi.org/10.3390/cancers14174240 |
_version_ | 1784785352611856384 |
---|---|
author | Ciccone, Valerio Filippelli, Arianna Bacchella, Chiara Monzani, Enrico Morbidelli, Lucia |
author_facet | Ciccone, Valerio Filippelli, Arianna Bacchella, Chiara Monzani, Enrico Morbidelli, Lucia |
author_sort | Ciccone, Valerio |
collection | PubMed |
description | SIMPLE SUMMARY: Nitric oxide (NO) plays a critical pathophysiological role in cancer by modulating several processes, such as angiogenesis, tumor growth, and metastatic potential. The aim of this study was to characterize the antitumor effects of a novel NO donor, [Zn(PipNONO)Cl], on the processes of epithelial– and endothelial–mesenchymal transitions (EMT and EndMT), known to actively participate in cancer progression. Two tumor cells lines were used in this study: human lung cancer cells (A549) and melanoma cells (A375), alone and co-cultured with human endothelial cells. Our results demonstrate that both tumor and endothelial cells were targets of NO action, which impaired EMT and EndMT functional and molecular features. Further studies are needed to finalize the therapeutic use of the novel NO donor. ABSTRACT: Exogenous nitric oxide appears a promising therapeutic approach to control cancer progression. Previously, a nickel-based nonoate, [Ni(SalPipNONO)], inhibited lung cancer cells, along with impairment of angiogenesis. The Zn(II) containing derivatives [Zn(PipNONO)Cl] exhibited a protective effect on vascular endothelium. Here, we have evaluated the antitumor properties of [Zn(PipNONO)Cl] in human lung cancer (A549) and melanoma (A375) cells. Metastasis initiates with the epithelial–mesenchymal transition (EMT) process, consisting of the acquisition of invasive and migratory properties by tumor cells. At not cytotoxic levels, the nonoate significantly impaired A549 and A375 EMT induced by transforming growth factor-β1 (TGF-β1). Reduction of the mesenchymal marker vimentin, upregulated by TGF-β1, and restoration of the epithelial marker E-cadherin, reduced by TGF-β1, were detected in both tumor cell lines in the presence of Zn-nonoate. Further, the endothelial–mesenchymal transition achieved in a tumor-endothelial cell co-culture was assessed. Endothelial cells co-cultured with A549 or A375 acquired a mesenchymal phenotype with increased vimentin, alpha smooth muscle actin and Smad2/3, and reduced VE-cadherin. The presence of [Zn(PipNONO)Cl] maintained a typical endothelial phenotype. In conclusion, [Zn(PipNONO)Cl] appears a promising therapeutic tool to control tumor growth and metastasis, by acting on both tumor and endothelial cells, reprogramming the cells toward their physiologic phenotypes. |
format | Online Article Text |
id | pubmed-9454450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94544502022-09-09 The Nitric Oxide Donor [Zn(PipNONO)Cl] Exhibits Antitumor Activity through Inhibition of Epithelial and Endothelial Mesenchymal Transitions Ciccone, Valerio Filippelli, Arianna Bacchella, Chiara Monzani, Enrico Morbidelli, Lucia Cancers (Basel) Article SIMPLE SUMMARY: Nitric oxide (NO) plays a critical pathophysiological role in cancer by modulating several processes, such as angiogenesis, tumor growth, and metastatic potential. The aim of this study was to characterize the antitumor effects of a novel NO donor, [Zn(PipNONO)Cl], on the processes of epithelial– and endothelial–mesenchymal transitions (EMT and EndMT), known to actively participate in cancer progression. Two tumor cells lines were used in this study: human lung cancer cells (A549) and melanoma cells (A375), alone and co-cultured with human endothelial cells. Our results demonstrate that both tumor and endothelial cells were targets of NO action, which impaired EMT and EndMT functional and molecular features. Further studies are needed to finalize the therapeutic use of the novel NO donor. ABSTRACT: Exogenous nitric oxide appears a promising therapeutic approach to control cancer progression. Previously, a nickel-based nonoate, [Ni(SalPipNONO)], inhibited lung cancer cells, along with impairment of angiogenesis. The Zn(II) containing derivatives [Zn(PipNONO)Cl] exhibited a protective effect on vascular endothelium. Here, we have evaluated the antitumor properties of [Zn(PipNONO)Cl] in human lung cancer (A549) and melanoma (A375) cells. Metastasis initiates with the epithelial–mesenchymal transition (EMT) process, consisting of the acquisition of invasive and migratory properties by tumor cells. At not cytotoxic levels, the nonoate significantly impaired A549 and A375 EMT induced by transforming growth factor-β1 (TGF-β1). Reduction of the mesenchymal marker vimentin, upregulated by TGF-β1, and restoration of the epithelial marker E-cadherin, reduced by TGF-β1, were detected in both tumor cell lines in the presence of Zn-nonoate. Further, the endothelial–mesenchymal transition achieved in a tumor-endothelial cell co-culture was assessed. Endothelial cells co-cultured with A549 or A375 acquired a mesenchymal phenotype with increased vimentin, alpha smooth muscle actin and Smad2/3, and reduced VE-cadherin. The presence of [Zn(PipNONO)Cl] maintained a typical endothelial phenotype. In conclusion, [Zn(PipNONO)Cl] appears a promising therapeutic tool to control tumor growth and metastasis, by acting on both tumor and endothelial cells, reprogramming the cells toward their physiologic phenotypes. MDPI 2022-08-31 /pmc/articles/PMC9454450/ /pubmed/36077778 http://dx.doi.org/10.3390/cancers14174240 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ciccone, Valerio Filippelli, Arianna Bacchella, Chiara Monzani, Enrico Morbidelli, Lucia The Nitric Oxide Donor [Zn(PipNONO)Cl] Exhibits Antitumor Activity through Inhibition of Epithelial and Endothelial Mesenchymal Transitions |
title | The Nitric Oxide Donor [Zn(PipNONO)Cl] Exhibits Antitumor Activity through Inhibition of Epithelial and Endothelial Mesenchymal Transitions |
title_full | The Nitric Oxide Donor [Zn(PipNONO)Cl] Exhibits Antitumor Activity through Inhibition of Epithelial and Endothelial Mesenchymal Transitions |
title_fullStr | The Nitric Oxide Donor [Zn(PipNONO)Cl] Exhibits Antitumor Activity through Inhibition of Epithelial and Endothelial Mesenchymal Transitions |
title_full_unstemmed | The Nitric Oxide Donor [Zn(PipNONO)Cl] Exhibits Antitumor Activity through Inhibition of Epithelial and Endothelial Mesenchymal Transitions |
title_short | The Nitric Oxide Donor [Zn(PipNONO)Cl] Exhibits Antitumor Activity through Inhibition of Epithelial and Endothelial Mesenchymal Transitions |
title_sort | nitric oxide donor [zn(pipnono)cl] exhibits antitumor activity through inhibition of epithelial and endothelial mesenchymal transitions |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454450/ https://www.ncbi.nlm.nih.gov/pubmed/36077778 http://dx.doi.org/10.3390/cancers14174240 |
work_keys_str_mv | AT cicconevalerio thenitricoxidedonorznpipnonoclexhibitsantitumoractivitythroughinhibitionofepithelialandendothelialmesenchymaltransitions AT filippelliarianna thenitricoxidedonorznpipnonoclexhibitsantitumoractivitythroughinhibitionofepithelialandendothelialmesenchymaltransitions AT bacchellachiara thenitricoxidedonorznpipnonoclexhibitsantitumoractivitythroughinhibitionofepithelialandendothelialmesenchymaltransitions AT monzanienrico thenitricoxidedonorznpipnonoclexhibitsantitumoractivitythroughinhibitionofepithelialandendothelialmesenchymaltransitions AT morbidellilucia thenitricoxidedonorznpipnonoclexhibitsantitumoractivitythroughinhibitionofepithelialandendothelialmesenchymaltransitions AT cicconevalerio nitricoxidedonorznpipnonoclexhibitsantitumoractivitythroughinhibitionofepithelialandendothelialmesenchymaltransitions AT filippelliarianna nitricoxidedonorznpipnonoclexhibitsantitumoractivitythroughinhibitionofepithelialandendothelialmesenchymaltransitions AT bacchellachiara nitricoxidedonorznpipnonoclexhibitsantitumoractivitythroughinhibitionofepithelialandendothelialmesenchymaltransitions AT monzanienrico nitricoxidedonorznpipnonoclexhibitsantitumoractivitythroughinhibitionofepithelialandendothelialmesenchymaltransitions AT morbidellilucia nitricoxidedonorznpipnonoclexhibitsantitumoractivitythroughinhibitionofepithelialandendothelialmesenchymaltransitions |